This report was first published by Endpoints News. To see the original version, click here
Insilico Medicine is having quite a month. Fresh from deals with Servier and Hygtia Therapeutics, the biotech has signed a new collaboration with Shanghai-based Qilu Pharmaceutical worth nearly $120 million.
The pact will see the partners use Insilico’s Pharma.AI drug discovery platform to develop small-molecule drugs for cardiometabolic diseases. The partners did not state exactly which conditions they intend to look at.
您已阅读32%（514字），剩余68%（1083字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。